Monthly
US$200
Billed every month
瑞舒伐他汀依折麦布片(I)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 2 applicationsNotification delivery: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders25View records ↓
Under-review filings15View records ↓
This year’s generic filers5View records ↓
NHSA approval numbers22View records ↓
API companies with A status0View records ↓
Chemical-drug catalogue
Loaded records: 25 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 24 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 优辉药业（北京）有限公司 | 广州玻思韬控释药业有限公司 | 国药准字H20265561 | 2026/08/04 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 齐鲁制药（海南）有限公司 | 齐鲁制药（海南）有限公司 | 国药准字H20265273 | 2026/07/21 | 每片含瑞舒伐他汀钙10mg(按C22H28FN3O6S计)与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 常州制药厂有限公司 | 常州制药厂有限公司 | 国药准字H20265225 | 2026/07/21 | 每片含瑞舒伐他汀钙 10mg（按C22H28FN3O6S计）与依折麦布 10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东鲁抗医药集团赛特有限责任公司 | 瑞华（中山）制药有限公司 | 国药准字H20265028 | 2026/06/30 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东齐都药业有限公司 | 广州玻思韬控释药业有限公司 | 国药准字H20264918 | 2026/06/23 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江京新药业股份有限公司 | 浙江京新药业股份有限公司 | 国药准字H20264978 | 2026/06/23 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏利泰尔药业有限公司 | 江苏利泰尔药业有限公司 | 国药准字H20264955 | 2026/06/23 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州沐源生物医药科技股份有限公司 | 新乡市常乐制药有限责任公司 | 国药准字H20264908 | 2026/06/23 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 常州市阳光药业有限公司 | 常州市阳光药业有限公司 | 国药准字H20264953 | 2026/06/23 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江西施美药业股份有限公司 | 江西施美药业股份有限公司 | 国药准字H20264748 | 2026/06/10 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江昂利康制药股份有限公司 | 浙江昂利康制药股份有限公司 | 国药准字H20264317 | 2026/05/12 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京海纳制药有限公司 | 南京海纳制药有限公司 | 国药准字H20264255 | 2026/05/07 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都倍特药业股份有限公司 | 成都倍特药业股份有限公司 | 国药准字H20264010 | 2026/04/14 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天大药业（珠海）有限公司 | 天大药业（珠海）有限公司 | 国药准字H20264004 | 2026/04/14 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏德源药业股份有限公司 | 江苏德源药业股份有限公司 | 国药准字H20263570 | 2026/03/10 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆圣华曦药业股份有限公司 | 重庆圣华曦药业股份有限公司 | 国药准字H20263420 | 2026/02/10 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天方药业有限公司 | 山东朗诺制药有限公司 | 国药准字H20256277 | 2025/12/16 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江诺得药业有限公司 | 浙江诺得药业有限公司 | 国药准字H20254797 | 2025/07/08 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京福元医药股份有限公司 | 北京福元医药股份有限公司 | 国药准字H20253967 | 2025/04/22 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Sanofi-Aventis Ireland Limited T/A SANOFI | Sanofi Ilac Sanayi ve Ticaret Anonim Sirketi | 国药准字HJ20230147 | 2023/12/26 | 每片含瑞舒伐他汀钙10mg（按瑞舒伐他汀计）与依折麦布10mg。 | Imported originator drug (进口原研药品) | CDE |
| 南京正大天晴制药有限公司 | 南京正大天晴制药有限公司 | 国药准字H20263565 | 2026/03/10 | 瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H20254910 | 2025/07/22 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）和依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北大医药股份有限公司 | 北大医药股份有限公司 | 国药准字H20266204 | 2026/10/13 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南尚众合生物医药有限公司 | 大桐制药（中国）有限责任公司 | 国药准字H20265754 | 2026/08/25 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 青岛黄海制药有限责任公司 | 复星医药（徐州）有限公司 | 国药准字H20265978 | 2026/09/15 | 每片含瑞舒伐他汀钙10mg（按C22H28FN3O6S计）与依折麦布10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 22 distinct approval numbers and 22 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京福元医药股份有限公司 | 国药准字H20253967 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010100177 | NHSA |
| 常州制药厂有限公司 | 国药准字H20265225 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010101397 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20263565 | 瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010101606 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20264010 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010102013 | NHSA |
| 石家庄四药有限公司 | 国药准字H20254910 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010102763 | NHSA |
| 天方药业有限公司 | 国药准字H20256277 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010103098 | NHSA |
| 山东鲁抗医药集团赛特有限责任公司 | 国药准字H20265028 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010104131 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20264918 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010104145 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20264317 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010104606 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20264978 | 每片含瑞舒伐他汀钙10mg(按 C₂₂H₂₈FN₃O₆S计)与依折麦布 10mg | Category B (乙) | XC10BAR128A001010104658 | NHSA |
| 江西施美药业股份有限公司 | 国药准字H20264748 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010105356 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20265273 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010105847 | NHSA |
| 江苏德源药业股份有限公司 | 国药准字H20263570 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010106632 | NHSA |
| 江苏利泰尔药业有限公司 | 国药准字H20264955 | 每片含瑞舒伐他汀钙10mg(按 C₂₂H₂₈FN₃O₆S计)与依折麦布 10mg | Category B (乙) | XC10BAR128A001010182291 | NHSA |
| Sanofi-Aventis Ireland Limited T/A SANOFI | 国药准字HJ20230147 | 每片含瑞舒伐他汀钙10mg(按瑞舒伐他汀计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010182826 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010183521 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20264908 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010184135 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20253967 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010200177 | NHSA |
| 常州制药厂有限公司 | 国药准字H20265225 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010201397 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20263565 | 瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010201606 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20264010 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010202013 | NHSA |
| 石家庄四药有限公司 | 国药准字H20254910 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010202763 | NHSA |
| 天方药业有限公司 | 国药准字H20256277 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010203098 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20264317 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010204606 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20264978 | 每片含瑞舒伐他汀钙10mg(按 C₂₂H₂₈FN₃O₆S计)与依折麦布 10mg | Category B (乙) | XC10BAR128A001010204658 | NHSA |
| 江苏德源药业股份有限公司 | 国药准字H20263570 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010206632 | NHSA |
| Sanofi-Aventis Ireland Limited T/A SANOFI | 国药准字HJ20230147 | 每片含瑞舒伐他汀钙10mg(按瑞舒伐他汀计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010282826 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010283521 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20264908 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010284135 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20253967 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010300177 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20263565 | 瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010301606 | NHSA |
| 石家庄四药有限公司 | 国药准字H20254910 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010302763 | NHSA |
| 天方药业有限公司 | 国药准字H20256277 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010303098 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20264317 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010304606 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20264978 | 每片含瑞舒伐他汀钙10mg(按 C₂₂H₂₈FN₃O₆S计)与依折麦布 10mg | Category B (乙) | XC10BAR128A001010304658 | NHSA |
| 江苏德源药业股份有限公司 | 国药准字H20263570 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010306632 | NHSA |
| Sanofi-Aventis Ireland Limited T/A SANOFI | 国药准字HJ20230147 | 每片含瑞舒伐他汀钙10mg(按瑞舒伐他汀计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010382826 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010383521 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20264908 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010384135 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20253967 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010400177 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20263565 | 瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010401606 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20264978 | 每片含瑞舒伐他汀钙10mg(按 C₂₂H₂₈FN₃O₆S计)与依折麦布 10mg | Category B (乙) | XC10BAR128A001010404658 | NHSA |
| 江苏德源药业股份有限公司 | 国药准字H20263570 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010406632 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010483521 | NHSA |
| 江苏德源药业股份有限公司 | 国药准字H20263570 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010506632 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010583521 | NHSA |
| 江苏德源药业股份有限公司 | 国药准字H20263570 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010606632 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001011083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001011183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001011283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001011383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001011483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001011583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001011683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001011783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001011883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001011983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001012083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001012183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001012283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001012383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001012483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001012583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001012683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001012783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001012883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001012983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001013083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001013183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001013283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001013383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001013483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20254797 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001013583521 | NHSA |
| 石家庄四药有限公司 | 国药准字H20254910 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001020102763 | NHSA |
| 山东鲁抗医药集团赛特有限责任公司 | 国药准字H20265028 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001020104131 | NHSA |
| 天大药业(珠海)有限公司 | 国药准字H20264004 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010100560 | NHSA |
| 青岛黄海制药有限责任公司 | 国药准字H20265978 | 每片含瑞舒伐他汀钙10mg(按 C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010104043 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20263420 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010109568 | NHSA |
| 常州市阳光药业有限公司 | 国药准字H20264953 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010109665 | NHSA |
| 优辉药业(北京)有限公司 | 国药准字H20265561 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010183203 | NHSA |
| 青岛黄海制药有限责任公司 | 国药准字H20265978 | 每片含瑞舒伐他汀钙10mg(按 C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010204043 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20263420 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010209568 | NHSA |
| 常州市阳光药业有限公司 | 国药准字H20264953 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010209665 | NHSA |
| 优辉药业(北京)有限公司 | 国药准字H20265561 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010283203 | NHSA |
| 青岛黄海制药有限责任公司 | 国药准字H20265978 | 每片含瑞舒伐他汀钙10mg(按 C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010304043 | NHSA |
| 常州市阳光药业有限公司 | 国药准字H20264953 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010309665 | NHSA |
| 优辉药业(北京)有限公司 | 国药准字H20265561 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010383203 | NHSA |
| 青岛黄海制药有限责任公司 | 国药准字H20265978 | 每片含瑞舒伐他汀钙10mg(按 C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010404043 | NHSA |
| 青岛黄海制药有限责任公司 | 国药准字H20265978 | 每片含瑞舒伐他汀钙10mg(按 C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001010504043 | NHSA |
| 天大药业(珠海)有限公司 | 国药准字H20264004 | 每片含瑞舒伐他汀钙10mg(按C₂₂H₂₈FN₃O₆S计)与依折麦布10mg | Category B (乙) | XC10BAR128A001020100560 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 15 filings and 15 distinct first applicants.
Generic 15
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 康普药业股份有限公司 | CYHS2503375 | Generic | 2025/09/12 | Not stated by source | CDE |
| 浙江英格莱制药有限公司 | CYHS2602446 | Generic | 2026/10/08 | Not stated by source | CDE |
| 江苏欧歌制药有限公司 | CYHS2601001 | Generic | 2026/04/29 | Not stated by source | CDE |
| 烟台鲁银药业有限公司 | CYHS2502442 | Generic | 2025/07/09 | Not stated by source | CDE |
| 山东新华制药股份有限公司;南京集萃剂鼎医药有限公司 | CYHS2502989 | Generic | 2025/08/15 | Not stated by source | CDE |
| 新乡市常乐制药有限责任公司 | CYHS2504493 | Generic | 2025/12/31 | Not stated by source | CDE |
| 海南葫芦娃药业集团股份有限公司 | CYHS2503700 | Generic | 2025/10/16 | Not stated by source | CDE |
| 广东江正药业有限公司;广州玻思韬控释药业有限公司 | CYHS2502735 | Generic | 2025/07/30 | Not stated by source | CDE |
| 云鹏医药集团有限公司 | CYHS2502691 | Generic | 2025/07/25 | Not stated by source | CDE |
| 四川科伦药业股份有限公司 | CYHS2500684 | Generic | 2025/02/09 | Not stated by source | CDE |
| 浙江浙北药业有限公司;安徽佳和药业有限公司 | CYHS2601871 | Generic | 2026/08/03 | Not stated by source | CDE |
| 安徽正善生物药业有限公司;大桐制药（中国）有限责任公司 | CYHS2600698 | Generic | 2026/03/23 | Not stated by source | CDE |
| 湖南千金湘江药业股份有限公司 | CYHS2600552 | Generic | 2026/02/27 | Not stated by source | CDE |
| 江西泰吉立生物医药科技有限公司;山西德元堂药业有限公司 | CYHS2504047 | Generic | 2025/11/24 | Not stated by source | CDE |
| 陕西白鹿制药股份有限公司 | CYHS2502858 | Generic | 2025/08/07 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 5 filings and 5 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 浙江英格莱制药有限公司 | CYHS2602446 | Generic | 2026/10/08 | Not stated by source | CDE |
| 江苏欧歌制药有限公司 | CYHS2601001 | Generic | 2026/04/29 | Not stated by source | CDE |
| 浙江浙北药业有限公司;安徽佳和药业有限公司 | CYHS2601871 | Generic | 2026/08/03 | Not stated by source | CDE |
| 安徽正善生物药业有限公司;大桐制药（中国）有限责任公司 | CYHS2600698 | Generic | 2026/03/23 | Not stated by source | CDE |
| 湖南千金湘江药业股份有限公司 | CYHS2600552 | Generic | 2026/02/27 | Not stated by source | CDE |
API registrations
Non-component matches: 0 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 依折麦布 | 江苏诺泰澳赛诺生物制药股份有限公司 | Y20260000100 | I | Component match (excluded from headline counts) | 2026/02/11 | CDE |
| 依折麦布 | 浙江天宇药业股份有限公司 | Y20250000915 | I | Component match (excluded from headline counts) | 2025/10/30 | CDE |
| 依折麦布 | 云鹏医药集团有限公司 | Y20250000047 | A | Component match (excluded from headline counts) | 2026/07/20 | CDE |
| 瑞舒伐他汀钙 | 安徽悦康凯悦制药有限公司 | Y20240001436 | A | Component match (excluded from headline counts) | 2026/07/27 | CDE |
| 依折麦布 | 天方药业有限公司 | Y20240001567 | A | Component match (excluded from headline counts) | 2026/07/14 | CDE |
| 瑞舒伐他汀钙 | 江苏普润生物医药有限公司 | Y20240001404 | A | Component match (excluded from headline counts) | 2026/07/27 | CDE |
| 依折麦布 | Saptagir Laboratories Pvt. Ltd. | Y20240000581 | I | Component match (excluded from headline counts) | 2026/04/03 | CDE |
| 瑞舒伐他汀钙 | M/s. Biocon Limited | Y20240000236 | I | Component match (excluded from headline counts) | 2024/03/21 | CDE |
| 依折麦布 | 浙江京圣药业有限公司 | Y20230001252 | A | Component match (excluded from headline counts) | 2025/07/11 | CDE |
| 瑞舒伐他汀钙 | Lee Pharma Limited | Y20230000872 | A | Component match (excluded from headline counts) | 2026/03/31 | CDE |
| 瑞舒伐他汀钙 | 浙江江北南海药业有限公司 | Y20230000714 | A | Component match (excluded from headline counts) | 2025/02/14 | CDE |
| 依折麦布 | 江苏德源药业股份有限公司 | Y20230000515 | A | Component match (excluded from headline counts) | 2024/09/02 | CDE |
| 依折麦布 | Apitoria Pharma Private Limited | Y20230000079 | A | Component match (excluded from headline counts) | 2025/01/06 | CDE |
| 依折麦布 | Hetero Labs Limited | Y20220000766 | A | Component match (excluded from headline counts) | 2026/03/19 | CDE |
| 依折麦布 | 亚宝药业集团股份有限公司 | Y20220000666 | A | Component match (excluded from headline counts) | 2026/02/10 | CDE |
| 瑞舒伐他汀钙 | 浙江江北药业有限公司 | Y20220000289 | A | Component match (excluded from headline counts) | 2023/09/27 | CDE |
| 依折麦布 | 南通常佑药业科技有限公司 | Y20210000966 | A | Component match (excluded from headline counts) | 2023/08/29 | CDE |
| 瑞舒伐他汀钙 | 浙江永太药业有限公司 | Y20210000962 | A | Component match (excluded from headline counts) | 2023/07/28 | CDE |
| 瑞舒伐他汀钙 | 云鹏医药集团有限公司 | Y20210000652 | A | Component match (excluded from headline counts) | 2024/11/28 | CDE |
| 瑞舒伐他汀钙 | 浙江乐普药业股份有限公司 | Y20210000578 | A | Component match (excluded from headline counts) | 2026/06/16 | CDE |
| 依折麦布 | Hanmi Fine Chemical Co., Ltd. | Y20200001433 | A | Component match (excluded from headline counts) | 2024/10/24 | CDE |
| 瑞舒伐他汀钙 | 宣城美诺华药业有限公司 | Y20210000329 | A | Component match (excluded from headline counts) | 2022/12/16 | CDE |
| 瑞舒伐他汀钙 | Hanmi Fine Chemical Co., Ltd. | Y20210000135 | A | Component match (excluded from headline counts) | 2024/08/07 | CDE |
| 依折麦布 | 山东新时代药业有限公司 | Y20210000182 | A | Component match (excluded from headline counts) | 2022/11/02 | CDE |
| 瑞舒伐他汀钙 | Sun Pharmaceutical Industries Limited | Y20210000168 | A | Component match (excluded from headline counts) | 2024/11/22 | CDE |
| 依折麦布 | 南京优科制药有限公司 | Y20210000199 | A | Component match (excluded from headline counts) | 2023/02/21 | CDE |
| 瑞舒伐他汀钙 | Centrient Pharmaceuticals India Private Limited | Y20210000015 | A | Component match (excluded from headline counts) | 2025/03/15 | CDE |
| 依折麦布 | LUPIN LIMITED | Y20210000140 | A | Component match (excluded from headline counts) | 2025/05/17 | CDE |
| 瑞舒伐他汀钙 | 河北广祥制药有限公司 | Y20210000024 | A | Component match (excluded from headline counts) | 2026/10/23 | CDE |
| 依折麦布 | 山东铂源药业股份有限公司 | Y20200001270 | A | Component match (excluded from headline counts) | 2024/02/27 | CDE |
| 依折麦布 | Synthimed Labs Private Limited | Y20200001218 | A | Component match (excluded from headline counts) | 2026/07/17 | CDE |
| 瑞舒伐他汀钙 | 南通常佑药业科技有限公司 | Y20200001398 | A | Component match (excluded from headline counts) | 2026/08/08 | CDE |
| 依折麦布 | Neuland Laboratories Ltd | Y20200000801 | I | Component match (excluded from headline counts) | 2020/12/22 | CDE |
| 瑞舒伐他汀钙 | 连云港贵科药业有限公司 | Y20200000654 | A | Component match (excluded from headline counts) | 2026/08/18 | CDE |
| 依折麦布 | 无锡福祈制药有限公司 | Y20200000290 | A | Component match (excluded from headline counts) | 2022/10/27 | CDE |
| 依折麦布 | 浙江天宇药业股份有限公司 | Y20190000721 | A | Component match (excluded from headline counts) | 2026/01/06 | CDE |
| 瑞舒伐他汀钙 | 天方药业有限公司 | Y20190000845 | A | Component match (excluded from headline counts) | 2026/07/17 | CDE |
| 瑞舒伐他汀钙 | 湖南九典宏阳制药有限公司 | Y20190021369 | A | Component match (excluded from headline counts) | 2025/11/18 | CDE |
| 瑞舒伐他汀钙 | MSN Laboratories Private Limited | Y20190000940 | A | Component match (excluded from headline counts) | 2025/05/24 | CDE |
| 瑞舒伐他汀钙 | 山东朗诺制药有限公司 | Y20190009618 | A | Component match (excluded from headline counts) | — | CDE |
| 瑞舒伐他汀钙 | 绍兴京新药业有限公司 | Y20190009351 | A | Component match (excluded from headline counts) | 2024/02/08 | CDE |
| 瑞舒伐他汀钙 | 浙江海正药业股份有限公司 | Y20190007514 | A | Component match (excluded from headline counts) | 2023/11/29 | CDE |
| 瑞舒伐他汀钙 | 连云港润众制药有限公司 | Y20190007277 | A | Component match (excluded from headline counts) | — | CDE |
| 瑞舒伐他汀钙 | 山东新时代药业有限公司 | Y20190007037 | A | Component match (excluded from headline counts) | 2022/10/28 | CDE |
| 瑞舒伐他汀钙 | 石药集团欧意药业有限公司 | Y20190007022 | A | Component match (excluded from headline counts) | — | CDE |
| 瑞舒伐他汀钙 | KRKA, d.d., Novo mesto | Y20180001608 | A | Component match (excluded from headline counts) | 2023/08/14 | CDE |
| 依折麦布 | 重庆圣华曦药业股份有限公司 | Y20190000874 | A | Component match (excluded from headline counts) | 2026/04/30 | CDE |
| 瑞舒伐他汀钙 | 先声药业有限公司 | Y20190000761 | A | Component match (excluded from headline counts) | 2025/08/14 | CDE |
| 瑞舒伐他汀钙 | 浙江美诺华药物化学有限公司 | Y20190000565 | A | Component match (excluded from headline counts) | 2026/04/13 | CDE |
| 依折麦布 | TEVA API INDIA PRIVATE LIMITED | Y20190000329 | A | Component match (excluded from headline counts) | 2026/07/15 | CDE |
| 依折麦布 | Aurobindo Pharma Limited | Y20180001595 | I | Component match (excluded from headline counts) | 2019/03/20 | CDE |
| 依折麦布 | 湖南方盛制药股份有限公司 | Y20190000024 | A | Component match (excluded from headline counts) | 2025/09/16 | CDE |
| 瑞舒伐他汀钙 | 乳源东阳光药业有限公司 | Y20180001564 | A | Component match (excluded from headline counts) | 2026/04/22 | CDE |
| 依折麦布 | MSN Laboratories Private Limited颐德药业（上海）有限公司 | Y20180001083 | A | Component match (excluded from headline counts) | 2025/07/30 | CDE |
| 依折麦布 | 山东朗诺制药有限公司 | Y20180001036 | I | Component match (excluded from headline counts) | 2018/08/30 | CDE |
| 瑞舒伐他汀钙 | 绍兴京新药业有限公司 | Y20180000877 | A | Component match (excluded from headline counts) | — | CDE |
| 瑞舒伐他汀钙 | 山东朗诺制药有限公司 | Y20170001976 | A | Component match (excluded from headline counts) | 2024/08/07 | CDE |
| 瑞舒伐他汀钙 | AstraZeneca UK Limited | Y20170001705 | A | Component match (excluded from headline counts) | 2023/08/23 | CDE |
| 瑞舒伐他汀钙 | 浙江江北药业有限公司 | Y20170001629 | A | Component match (excluded from headline counts) | 2024/05/01 | CDE |
| 瑞舒伐他汀钙 | 南京优科制药有限公司 | Y20170001088 | A | Component match (excluded from headline counts) | 2025/12/03 | CDE |
| 瑞舒伐他汀钙 | 常州制药厂有限公司 | Y20170000215 | A | Component match (excluded from headline counts) | 2024/03/14 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/10/28Notification delivery
福建东瑞制药有限公司
CYHS2504042
Fact date: 2026/10/28 (Publication date) · Publication date: 2026/10/28 · Site observation date: 2026/11/03
Notification delivered; the specific outcome remains to be checked.
View source · Table row 16 ↗ -
2026/10/08Accepted
-
2026/09/11Accepted
河北新石制药有限公司;南京海纳制药有限公司
CYHB2601727
Fact date: 2026/09/11 · Site observation date: 2026/10/21
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to this drug
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy